Kinase-inhibitor–insensitive cancer stem cells in chronic myeloid leukemia
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Kinase-inhibitor–insensitive cancer stem cells in chronic myeloid leukemia
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 14, Issue 3, Pages 287-299
Publisher
Informa Healthcare
Online
2014-01-04
DOI
10.1517/14712598.2014.867323
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
- (2013) K. Cramer-Morales et al. BLOOD
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells
- (2013) E. Bolton-Gillespie et al. BLOOD
- A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition
- (2013) Daniel J. Goff et al. Cell Stem Cell
- BCL-2 Inhibition: Stemming the Tide of Myeloid Malignancies
- (2013) Leah J. Hogdal et al. Cell Stem Cell
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
- (2013) Paolo Neviani et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex
- (2013) Min Chen et al. JNCI-Journal of the National Cancer Institute
- Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice
- (2012) C. Walz et al. BLOOD
- Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining
- (2012) S. Chakraborty et al. BLOOD
- Targeting of GSK3 promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells
- (2012) G. Reddiconto et al. BLOOD
- Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
- (2012) A. Agarwal et al. BLOOD
- HIF1 is required for survival maintenance of chronic myeloid leukemia stem cells
- (2012) H. Zhang et al. BLOOD
- Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
- (2012) Florian H. Heidel et al. Cell Stem Cell
- Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: Key role of stromal microenvironment
- (2012) P.F. Seke Etet et al. CELLULAR SIGNALLING
- Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib
- (2012) Susan Branford et al. JOURNAL OF CLINICAL ONCOLOGY
- Standardized definitions of molecular response in chronic myeloid leukemia
- (2012) N C P Cross et al. LEUKEMIA
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
- (2012) R A Larson et al. LEUKEMIA
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML
- (2011) G. V. Helgason et al. BLOOD
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
- (2011) E. A. Nelson et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Suboptimal responses in chronic myeloid leukemia
- (2011) Elias Jabbour et al. CANCER
- The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia
- (2011) Yaoyu Chen et al. CELL CYCLE
- BMI1 as a novel target for drug discovery in cancer
- (2011) Liangxian Cao et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
- (2011) Bing Long et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
- (2011) Christian Hurtz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells
- (2011) F Pellicano et al. LEUKEMIA
- Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib
- (2011) E Weisberg et al. LEUKEMIA
- BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition
- (2011) Cihangir Duy et al. NATURE
- Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate
- (2010) X. Jiang et al. BLOOD
- Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
- (2010) Bin Zhang et al. CANCER CELL
- Oxygen in Stem Cell Biology: A Critical Component of the Stem Cell Niche
- (2010) Ahmed Mohyeldin et al. Cell Stem Cell
- Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis
- (2010) F. Vianello et al. HAEMATOLOGICA
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- BCR-ABL kinase is dead; long live the CML stem cell
- (2010) Alexander Perl et al. JOURNAL OF CLINICAL INVESTIGATION
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia
- (2010) Makoto Kashimura et al. LEUKEMIA RESEARCH
- TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
- (2010) Kazuhito Naka et al. NATURE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- The leukemic stem cell niche: current concepts and therapeutic opportunities
- (2009) S. W. Lane et al. BLOOD
- A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell
- (2009) Keisuke Ito et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib
- (2009) Sophia Hatziieremia et al. EXPERIMENTAL HEMATOLOGY
- The hematopoietic stem cell niche: Low in oxygen but a nice place to be
- (2009) Pernilla Eliasson et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
- (2009) Cristian Bellodi et al. JOURNAL OF CLINICAL INVESTIGATION
- Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
- (2009) A Davies et al. LEUKEMIA
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
- (2009) Chen Zhao et al. NATURE
- Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
- (2009) Yaoyu Chen et al. NATURE GENETICS
- β-Catenin Expression in the Bone Marrow Microenvironment Is Required for Long-Term Maintenance of Primitive Hematopoietic Cells
- (2009) Michael J. Nemeth et al. STEM CELLS
- Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
- (2008) S. M. Devine et al. BLOOD
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
- (2008) Christine Dierks et al. CANCER CELL
- β-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia
- (2008) Y Hu et al. LEUKEMIA
- Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors
- (2008) H Konig et al. LEUKEMIA
- Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107
- (2008) Meir Wetzler et al. LEUKEMIA & LYMPHOMA
- CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
- (2008) L. Jin et al. MOLECULAR CANCER THERAPEUTICS
- PML targeting eradicates quiescent leukaemia-initiating cells
- (2008) Keisuke Ito et al. NATURE
- A brief introduction to FOXOlogy
- (2008) B M Th Burgering ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started